Ascendis Pharma A/S (ASND) Hedge Fund Ownership (Q2 2026)

Ascendis Pharma A/S (ASND)

12 + Investors. Track Smart Money conviction in ASND. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ASND

Based on 315 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added ASND than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

315 hedge funds hold ASND right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +27% more funds vs a year ago

fund count last 6Q

+66 new funds entered over the past year (+27% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 56% buying

198 buying154 selling

Last quarter: 198 funds bought or added vs 154 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

📈

More new buyers each quarter (+55 vs last Q)

new funds entering per quarter

Funds opening a new ASND position: 62 → 58 → 35 → 90. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 23% medium ■ 29% new

152 out of 315 hedge funds have held ASND for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +25% but shares only +7% — price-driven

Value

+25%

+7%

Last quarter: the total dollar value of institutional holdings rose +25%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

➡️

Steady discovery — ~90 new funds/quarter

45 → 62 → 58 → 35 → 90 new funds/Q

New funds entering each quarter: 62 → 58 → 35 → 90. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 58% veterans vs 30% newcomers

■ 58% veterans ■ 12% 1-2yr ■ 30% new

Entry-cohort mix of 335 holders: 193 (58%) are 2+ year veterans, 41 entered 1–2 years ago, and 101 (30%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 40% AUM from top-100 funds

40% from top-100 AUM funds

54 of 313 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in ASND. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.8

out of 10

Low Exit Risk

Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	12	271	-95.57%
13F Shares	1M	55M	-98.09%
Total Value	$282M	$12.58B	-97.76%
New Positions	4	34	-30
Increased Positions	4	109	-105
Closed Positions	263	70	+193
Reduced Positions	0	103	-103
Total Calls	0	15	-100.0%
Total Puts	0	10	-100.0%
PUT/CALL Ratio	0.0	0.67	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

271

-95.57%

13F Shares

55M

-98.09%

Total Value

$282M

$12.58B

-97.76%

New Positions

-30

Increased Positions

109

-105

Closed Positions

263

+193

Reduced Positions

103

-103

Total Calls

-100.0%

Total Puts

-100.0%

PUT/CALL Ratio

0.0

0.67

Bullish

Institutional Holders (2026 Q2)

12 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ASND. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ASND holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Ra Capital Management, L.P.	23.83%	10,281,496	$2.74B
2	Resolute Capital Asset Partners LLC	13.52%	118,627	$31.6M
3	Avoro Capital Advisors LLC	12.24%	5,111,111	$1.36B
4	Tri Locum Partners LP	8.49%	258,740	$69.0M
5	Silverarc Capital Management, LLC	5.72%	206,234	$55.0M
6	PFM Health Sciences, LP	5.34%	233,171	$62.2M
7	Eagle Health Investments LP	4.69%	106,158	$28.3M
8	Perceptive Advisors LLC	4.66%	1,163,721	$310.4M
9	Westfield Capital Management Co LP	4.18%	4,798,267	$1.28B
10	Defilade Capital Management, L.P.	3.39%	94,843	$25.3M
11	Spyglass Capital Management LLC	3.11%	215,398	$57.5M
12	Evolutionary Tree Capital Management, LLC	3.04%	6,049	$1.6M
13	Matisse Capital	3.00%	28,107	$7.5M
14	First Turn Management, LLC	2.99%	104,877	$28.0M
15	Nan Fung Group Holdings Ltd	2.76%	13,600	$3.6M
16	DAFNA Capital Management LLC	2.47%	48,469	$12.9M
17	ARS Investment Partners, LLC	2.45%	210,462	$56.1M
18	Vestal Point Capital, LP	2.34%	375,000	$100.0M
19	Synergy Asset Management, LLC	2.29%	91,228	$24.3M
20	Rock Springs Capital Management LP	2.20%	168,750	$45.0M
21	Rice Hall James & Associates, LLC	1.93%	148,644	$39.6M
22	Catalio Capital Management, LP	1.59%	31,759	$8.5M
23	Oddo Bhf Asset Management Sas	1.59%	128,657	$34.3M
24	Henry James International Management Inc.	1.36%	16,987	$4.5M
25	Frazier Life Sciences Management, L.P.	1.31%	225,155	$60.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Ascendis Pharma A/S (ASND)

What does the Smart Money Trend signal show for ASND?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added ASND than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ASND?

Slight buying edge — 56% buying: Last quarter: 198 funds bought or added vs 154 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ASND holders?

Elite ownership — 40% AUM from top-100 funds: 54 of 313 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in ASND. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ASND?

48% of holders stayed for 2+ years: 152 out of 315 hedge funds have held ASND for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Ascendis Pharma A/S (ASND)

Smart Money Signals — ASND

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Fast accumulation — +27% more funds vs a year ago

Slight buying edge — 56% buying

More new buyers each quarter (+55 vs last Q)

48% of holders stayed for 2+ years

Value +25% but shares only +7% — price-driven

Steady discovery — ~90 new funds/quarter

Veteran-anchored — 58% veterans vs 30% newcomers

Elite ownership — 40% AUM from top-100 funds

Institutional Sentiment Summary — ASND

Hedge Fund Ownership: ASND

Market Analysis: ASND

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ASND

Hedge Fund Positioning: ASND

Statistics: ASND

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Stocks with similar institutional ownership

Frequently Asked Questions — Ascendis Pharma A/S (ASND)

Welcome to 13Foresight!